Home » Stocks » BMEA

Biomea Fusion, Inc. (BMEA)

Stock Price: $18.60 USD 1.60 (9.41%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $18.79 +0.19 (1.02%) Apr 16, 7:58 PM
Market Cap 535.08M
Revenue (ttm) n/a
Net Income (ttm) -5.32M
Shares Out 28.77M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $18.60
IPO Price $17.00
Change ($) 1.60
Change (%) 9.41%
Day's Open 20.00
Day's Range 16.55 - 22.22
Day's Volume 3,590,103
52-Week Range 16.55 - 22.22

News

Hide News

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company...

1 day ago - GlobeNewswire

Biomea Fusion, Inc. has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

About BMEA

Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. An irreversible small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. We built our proprietary FUSION ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 16, 2021
CEO
Thomas Butler
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
BMEA
Full Company Profile

Financial Performance

Financial Statements